Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S††Electronic supplementary information (ESI) available. CCDC 1876852. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03445e
Sign Up to like & getrecommendations! Published in 2019 at "Chemical Science"
DOI: 10.1039/c9sc03445e
Abstract: We present inhibitors of drug resistant mutants of EGFR including T790M and C797S. In addition, we present the first X-ray crystal structures of covalent inhibitors in complex with C797S-mutated EGFR to gain insight into their… read more here.
Keywords: osimertinib resistant; c797s; t790m c797s; esi ... See more keywords
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221079125
Abstract: Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR-mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in NSCLC… read more here.
Keywords: preclinical models; patients patient; resistance; patient derived ... See more keywords